Bookmark and Share
Guanethidine (CID 3518) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(4)
 
 
Inactive(177)
 
 
Inconclusive(22)
 
 
Unspecified(275)
 
 
Top Targets:
7TM GPCR Srx(17)
 
 
p450(17)
 
 
 
7TM GPCR Srsx(15)
 
 
HSD10-like SD..(4)
 
 
STKc ERK1 2 l..(4)
 
 
 
BioAssay Types:
Confirmatory(223)
 
 
 
 
Literature(136)
 
 
 
 
 
Screening(1)
 
 
BioActivity Types:
IC50(133)
 
 
 
 
Potency(81)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 407    Data Row: 478   Total Pages: 24   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103203421]
NO releasing ability of compound measured through formation of nitrite using iNOS (nitric oxide synthases) [AID92306, Type: Literature]
View
2
[SID103203421]
NO releasing ability of compound measured through formation of nitrite using nNOS (nitric oxide synthases) [AID146288, Type: Literature]
View
3
[SID48416075]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
4
[SID85209451]
Ligands of bioamine (Class A) GPCRs [AID2062, Type: other]
View
5
[SID103203421]
Distribution in dog adrenal medulla 30 min after administration. [AID15565, Type: Literature]
View
6
[SID103203421]
Distribution in dog adrenal medulla 72 hours after administration. [AID15566, Type: Literature]
View
7
[SID11112157]
Cytochrome panel assay with activity outcomes [AID1851, Type: other]
View
8
[SID103203421]
IC50 DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) [AID625194, Type: confirmatory]Adenosine receptor A1 [gi:231473]
View
9
[SID103203421]
IC50 DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) [AID625180, Type: confirmatory]Mitogen-activated protein kinase 3 [gi:232066]
View
10
[SID103203421]
IC50 DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) [AID625174, Type: confirmatory]Caspase-1 [gi:266321]
View
11
[SID103203421]
IC50 DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) [AID625159, Type: confirmatory]Nitric oxide synthase, brain [gi:266646]
View
12
[SID103203421]
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) [AID625160, Type: other]Nitric oxide synthase, inducible [gi:266649]
View
13
[SID103203421]
IC50 DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) [AID625256, Type: confirmatory]Sodium-dependent dopamine transporter [gi:266667]
View
14
[SID103203421]
IC50 DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) [AID625222, Type: confirmatory]Sodium-dependent serotonin transporter [gi:400630]
View
15
[SID103203421]
IC50 DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) [AID625242, Type: confirmatory]Cholecystokinin receptor type A [gi:416772]
View
16
[SID103203421]
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) [AID625232, Type: other]Vasoactive intestinal polypeptide receptor 1 [gi:418253]
View
17
[SID103203421]
IC50 DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) [AID625206, Type: confirmatory]Beta-3 adrenergic receptor [gi:461604]
View
18
[SID103203421]
IC50 DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) [AID625192, Type: confirmatory]5-hydroxytryptamine receptor 2A [gi:543727]
View
19
[SID103203421]
IC50 DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) [AID625199, Type: confirmatory]Alpha-1B adrenergic receptor [gi:543734]
View
20
[SID103203421]
IC50 DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) [AID625195, Type: confirmatory]Adenosine receptor A2a [gi:543740]
View